Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13721714 | 0.77 | L3MBTL1 (0.59) | L3MBTL1SMN1; SMN2HTTMAPTMEN1 | |
| SCHEMBL13720705 | 0.75 | KMT2A (0.37) | NPC1RAB9ASMN1; SMN2HTTMAPT | |
| SCHEMBL13721601 | 0.74 | L3MBTL1 (0.54) | L3MBTL1NPC1RAB9ASMN1; SMN2HTT | |
| SCHEMBL19865577 | 0.73 | LPL (0.31) | — | |
| SCHEMBL21090587 | 0.73 | LPL (0.35) | — | |
| SCHEMBL4977958 | 0.72 | LPL (0.40) | — | |
| SCHEMBL19865293 | 0.71 | LPL (0.41) | — | |
| SCHEMBL21090923 | 0.69 | LPL (0.32) | — | |
| SCHEMBL18354582 | 0.68 | CES2 (0.31) | — | |
| SCHEMBL7733701 | 0.68 | L3MBTL1 (1.00) | L3MBTL1NPC1RAB9ASMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012155042-A2 | NOVEL BORATE DERIVATIVES AND THEIR APPLICATIONS | ANDERSON DEVELOPMENT COMPANY (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120289733-A1 | NOVEL BORATE DERIVATIVES AND THEIR APPLICATIONS | ANDERSON DEVELOPMENT COMPANY (US) | 2012-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289733-A1 | NOVEL BORATE DERIVATIVES AND THEIR APPLICATIONS | BRS3, BRSK1, CA4 | L3MBTL1 886/4885NPC1 1191/4885RAB9A 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.